Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
|ClinicalTrials.gov Identifier: NCT00875615|
Recruitment Status : Completed
First Posted : April 3, 2009
Results First Posted : October 17, 2013
Last Update Posted : February 7, 2017
RATIONALE: Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Infusing chemotherapy directly into the liver and giving it together with sorafenib may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects of infusing cisplatin or carboplatin directly into the liver and giving it together with sorafenib in treating patients with liver cancer that cannot be removed by surgery.
|Condition or disease||Intervention/treatment||Phase|
|Liver Cancer||Drug: Carboplatin Drug: Cisplatin Drug: Sorafenib||Phase 2|
- To assess the safety of intrahepatic arterial infusion of cisplatin or carboplatin in combination with sorafenib tosylate in patients with unresectable hepatocellular carcinoma.
- To assess the time to tumor progression in patients treated with this regimen.
- To assess the overall and progression-free survival of patients treated with this regimen.
OUTLINE: Patients receive intrahepatic arterial infusion of cisplatin or carboplatin over 30-45 minutes on day 1 and oral sorafenib tosylate twice daily on days 8-35. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Intrahepatic Artery Chemotherapy With Nexavar in Hepatocellular Carcinoma Patients|
|Study Start Date :||December 2008|
|Primary Completion Date :||June 2012|
|Study Completion Date :||June 2012|
|Experimental: Cisplatin or Carboplatin + Sorafenib||
Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.Drug: Cisplatin
Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.Drug: Sorafenib
Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
- Number of Subjects Experiencing Adverse Events [ Time Frame: 36 months ]The number of subjects experiencing adverse events after receiving protocol therapy.
- Number of Patients Achieving Clinical Benefit [ Time Frame: 36 months ]Number of patients achieving complete or partial response according to RECIST criteria
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00875615
|United States, Florida|
|University of Miami Sylvester Comprehensive Cancer Center - Miami|
|Miami, Florida, United States, 33136|
|Principal Investigator:||Lynn G. Feun, MD||University of Miami Sylvester Comprehensive Cancer Center|